Immunotherapy in Glioblastoma: A Clinical Perspective.

Details

Ressource 1Download: 34359621_BIB_89F18E1BB4ED.pdf (1047.23 [Ko])
State: Public
Version: Final published version
License: CC BY 4.0
Serval ID
serval:BIB_89F18E1BB4ED
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Immunotherapy in Glioblastoma: A Clinical Perspective.
Journal
Cancers
Author(s)
Desbaillets N., Hottinger A.F.
ISSN
2072-6694 (Print)
ISSN-L
2072-6694
Publication state
Published
Issued date
24/07/2021
Peer-reviewed
Oui
Volume
13
Number
15
Pages
3721
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: epublish
Abstract
Glioblastoma is the most frequent and the most aggressive brain tumor. It is notoriously resistant to current treatments, and the prognosis remains dismal. Immunotherapies have revolutionized the treatment of numerous cancer types and generate great hope for glioblastoma, alas without success until now. In this review, the rationale underlying immune targeting of glioblastoma, as well as the challenges faced when targeting these highly immunosuppressive tumors, are discussed. Innovative immune-targeting strategies including cancer vaccines, oncolytic viruses, checkpoint blockade inhibitors, adoptive cell transfer, and CAR T cells that have been investigated in glioblastoma are reviewed. From a clinical perspective, key clinical trial findings and ongoing trials are discussed for each approach. Finally, limitations, either biological or arising from trial designs are analyzed, and strategies to overcome them are presented. Proof of efficacy for immunotherapy approaches remains to be demonstrated in glioblastoma, but our rapidly expanding understanding of its biology, its immune microenvironment, and the emergence of novel promising combinatorial approaches might allow researchers to finally fulfill the medical need for GBM patients.
Keywords
CAR T cell, checkpoint inhibitor, glioblastoma, immunotherapy, oncolytic virus, vaccine
Pubmed
Web of science
Open Access
Yes
Create date
13/08/2021 15:14
Last modification date
12/01/2022 8:11
Usage data